CLSDQ (Clearside Biomedical) DeferredTaxAndRevenue: $0.00 Mil (As of Sep. 2025)


CLSDQ Clearside Biomedical Inc CLSDQ
49 GF Score
Price $0.13
GF Value $6.34
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical DeferredTaxAndRevenue?

Clearside Biomedical CLSDQ 49 DeferredTaxAndRevenue is $0.00 Mil as of Sep. 2025. GuruFocus rates CLSDQ with a GF Score™ of 49/100 and a GF Value™ of $6.34 (Possible Value Trap). The stock has 7 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Clearside Biomedical's current deferred tax and revenue for the quarter that ended in Sep. 2025 was $0.00 Mil.

Clearside Biomedical DeferredTaxAndRevenue Related Terms

Clearside Biomedical DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Clearside Biomedical's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearside Biomedical DeferredTaxAndRevenue Chart

Clearside Biomedical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 0.00 0.21 0.08 0.00

Clearside Biomedical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLSDQ
49GF Score
Clearside Biomedical Inc CLSDQ
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
Clearside Biomedical (CLSDQ) has a DeferredTaxAndRevenue of $0.00 Mil as of Sep. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Clearside Biomedical.
Is Clearside Biomedical's DeferredTaxAndRevenue too high?
Clearside Biomedical's current DeferredTaxAndRevenue is $0.00 Mil. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's DeferredTaxAndRevenue compare to LYRA and EVFM?
Clearside Biomedical's DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Clearside Biomedical. Clearside Biomedical's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current DeferredTaxAndRevenue is $0.00 Mil. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current DeferredTaxAndRevenue is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clearside Biomedical (CLSDQ) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34. GuruFocus considers Clearside Biomedical to be Possible Value Trap.

Key valuation signals for CLSDQ:

  • DeferredTaxAndRevenue: $0.00 Mil
  • GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clearside Biomedical Business Description

Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for CLSDQ

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$6.34
GF Value